New Breakthrough Antibiotic Can Treat Drug-Resistant 'Super Gonorrhoea'
Gonorrhoea is one of several sexually transmitted infections which is fast-gaining resistance to existing antibiotic treatments, making it hard to effectively treat patients with drug-resistant strains of Neisseria gonorrhoeae, the bacteria responsible for the infection. The infection was listed as a 'high' priority in the World Health Organization's Bacterial Priority Pathogens List, 2024. Between 600,000-700,000 cases of gonorrhoea are diagnosed in the U.S. each year according to the CDC.
'Gonorrhoea has developed resistance to nearly all the antibiotics used for its treatment,' according to the CDC website. 'We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common infection. This is an urgent public health threat because gonorrhoea control in the United States largely relies on our ability to successfully treat the infection.'
The newly developed treatment, called gepotidacin, may offer a much-needed alternative to standard gonorrhoea therapies, particularly in light of rising global resistance to existing drugs. Just a few weeks ago, gepotidacin was approved by the FDA for the treatment of urinary tract infections in women and children, following positive trial results.
The findings, published in The Lancet and also presented at the 2025 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference in Vienna earlier this week, come from a phase 3 clinical trial involving over 600 patients across six countries including the U.K. and the U.S. Gepotidacin works by stopping bacterial DNA replication, essentially stopping the division and multiplication of bacteria.
Researchers compared gepotidacin, taken orally, to the current standard treatment combination: an injection of ceftriaxone combined with an oral dose of azithromycin. The study concluded that gepotidacin was as effective as the existing treatment combination and importantly, worked against strains of Neisseria gonorrhoeae known to be resistant to the currently recommended treatment.
The treatment was found to be safe with no significant side-effects and the authors of the study also note that gepotidacin is only taken orally and could remove the need for an injection, making the treatment more accessible for patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
a minute ago
- CBS News
Teens who vape have higher rates of depression and anxiety, new research says
Wrapped in fruity flavors and sleek designs, e-cigarettes have been drawing in young people for years and new research finds teenagers who vape have higher rates of depression and anxiety. "It's small, it's portable, it's got tons of flavors," said Lyn Powell, a vaper in Boston. "Almost everybody I know got a vape — or if they don't have a vape, they're trying to hit somebody's vape." Walking in the Fenway area Friday afternoon, he told WBZ-TV it's the convenience that keeps him vaping. "You don't gotta light nothing, there's no smell. You can do it in the bathroom, in buildings, it's just more convenient," said Powell. But Brian King, Executive Vice President at Tobacco-Free Kids, said flavors are what hook young users. "The advertising will lead a horse to water, the flavors will get them to drink — and the nicotine keeps them coming back for more," King said. According to FDA data, more than 1.6 million kids still use e-cigarettes, and nearly 90% of them use a flavored product. "[It declined] from about over 5 million kids in 2019, down to about 1.6 million kids," King said. "But bad news is we've still got more work to do." Unlike traditional cigarettes — "Where many times, some of the more serious risks can be decades away like lung cancer," explained Dr. Alexia Arauz Boudreau, a primary care pediatrician at Massachusetts General Hospital, she said vaping can affect health immediately. "It actively changes your brain chemistry. Teens or anybody who uses are at risk about getting chemical lung burns." To curb access, in 2020, Massachusetts made history banning retail stores from selling flavored tobacco products, including menthol cigarettes, flavored cigars, and flavored e-cigarettes. However, Powell says it is still possible to get them. "A lot of stores sell them under the table," he said. "And the police really don't care." On Friday afternoon, WBZ-TV reporter Samantha Chaney bought a strawberry ice flavored vape from a convenience store in Boston-- they didn't even ask her for ID. King said there's no single fix to this issue — but a united front can make a difference. "Ultimately, it's going to be that coordinated approach that's going to work," he said. "And it's a good reminder that we have to redouble our efforts."
Yahoo
an hour ago
- Yahoo
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Trump Administration Sues NYC Over Sanctuary City Policy On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P. Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
FDA Investigates Death of Boy Who Got Sarepta's Gene Therapy
US regulators said they are investigating the death of an 8-year-old boy who received a gene therapy from Sarepta Therapeutics Inc. The death occurred on June 7, according to a statement from the US Food and Drug Administration.
